ARA-290
16mg
- Ships same or next day Orders before 3PM EST, FedEx 2-Day Air
- Verify this lot View the lab reports · View the Vanguard certificate
- Real U.S. support Live chat and email, 7 days a week
For research use only. Not for human or veterinary consumption.
- PURITY: 99%+
- CAS: 1208243-50-8
- FORM: LYOPHILIZED POWDER (Acetate Salt)
- DOSAGE: 16 MG
- PURITY: 99%+
| ARA-290 16MG | |
|---|---|
| SKU | CP_ARA_290_3ML_VIAL |
| CATEGORY | Lyophilized Peptide |
| CAS | 1208243-50-8 |
| VIAL SIZE | 3 mL |
| FORM | LYOPHILIZED POWDER (Acetate Salt) |
| MOLECULAR WEIGHT | 1257.3 g/mol |
| SEQUENCE | Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (N-terminal pyroglutamate cap) |
| MOLECULAR FORMULA | C51H84N16O21 |
| ITEM ID | 17040 |
ARA-290 16MG provides ARA-290 (Cibinetide) as lyophilized powder in a 3 mL vial.
Receptor Selectivity and Signaling Context
ARA-290 is studied in nonclinical systems as a ligand for the EPOR/CD131 heteromeric receptor complex. Downstream signaling cascades investigated in experimental models include JAK2, PI3K/Akt, and NF-κB-associated pathways. This reported receptor selectivity distinguishes ARA-290 from full-length EPO in experimental paradigms examining non-erythropoietic receptor-mediated signaling.
Selected Nonclinical Research Findings
In Vitro: Cisplatin-Induced Cell Stress Model
Ghassemi-Barghi et al. (2023) evaluated ARA-290 in HEK-293 and ACHN cell lines exposed to cisplatin. ARA-290 pretreatment was associated with reduced DNA damage parameters (comet assay, micronucleus frequency), decreased malondialdehyde and reactive oxygen species levels, and increased antioxidant enzyme activity compared to cisplatin-only controls. Pro-inflammatory cytokine levels (TNFα, IL-6, IL-1β) and caspase-3 activity were lower in ARA-290-treated groups. Gene and protein expression analysis showed decreased Bax and increased Bcl2 levels relative to cisplatin-only groups [36085231].
In Vitro and In Vivo: Osteoclastogenesis and Bone Measurements
Awida et al. (2021) examined cibinetide in murine bone marrow-derived osteoclast precursor cultures and in C57BL/6J female mice. In vitro, cibinetide inhibited osteoclastogenesis when administered alone or in combination with EPO. In vivo, cibinetide-treated mice showed higher cortical and trabecular bone mineral density measurements compared to controls. Flow cytometry indicated reduced osteoclast progenitor populations (Lin⁻ CD11b⁻ Ly6Cʰⁱ CD115⁺) in mice receiving cibinetide plus EPO versus EPO alone [35008482].
In Vivo: Monocyte Modulation in APP/PS1 Mice
Al-Onaizi et al. (2022) administered ARA-290 systemically to young APP/PS1 transgenic mice. ARA-290 increased circulating Ly6Cˡᵒʷ patrolling monocyte levels and monocyte progenitors in bone marrow. Amyloid-β burden was reduced in treated animals compared to controls. In chimeric APP/PS1 mice with selective Ly6Cˡᵒʷ monocyte depletion, ARA-290 did not produce these changes, suggesting dependence on this monocyte subset. ARA-290 was not associated with similar outcomes when administered to aged APP/PS1 mice with advanced pathology [34343617].
Sale